Loading clinical trials...
Loading clinical trials...
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT07537348 · Advanced Gastric Cancer
NCT07259226 · Advanced Breast Cancer, Advanced Gastric Cancer, and more
NCT07102901 · Advanced Gastric Cancer, Metastatic Gastric Cancer, and more
NCT06947291 · Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
NCT06767436 · Advanced Gastric Cancer
Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
Fayetteville, Arkansas
Loma Linda Oncology Medical Group Loma Linda
Redlands, California
Henry Ford Hospital Dept. of Henry Ford Hospital
Detroit, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions